/CALC
CALC Stock - CalciMedica, Inc.
Healthcare|BiotechnologyNASDAQ
$6.35+29.59%
+$1.45 (+29.59%) • Dec 19
85
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.75
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+4089.0%upside
Target: $266.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CALC
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$6.29 – $6.41
TARGET (TP)$266.00
STOP LOSS$5.84
RISK/REWARD1:509.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.12
52W High$6.40
52W Low$1.42
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | $-519,000 | $-395,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-24,204,000 | $-38,075,000 | $-14,193,000 | $-35,947,000 | $-29,832,000 |
| Net Income | $-13,700,000 | $-34,357,000 | $-7,824,000 | $-35,821,000 | $-27,531,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.22 | $-7.65 | $-23.20 | $-23.66 | $-73.50 |
Company Overview
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CALCBeat Rate
58%
Last 19 quarters
Avg Surprise
-155.1%
EPS vs Estimate
Beats / Misses
11/7
1 met exactly
Latest EPS
$-0.39
Q4 2025
EPS Surprise History
Q1 24
+77.0%
$-0.23vs$-1.00
Q2 24
+14.0%
$-0.43vs$-0.50
Q3 24
+5.5%
$-0.52vs$-0.55
Q4 24
+18.0%
$-0.50vs$-0.61
Q1 25
+29.2%
$-0.34vs$-0.48
Q2 25
+16.3%
$-0.36vs$-0.43
Q3 25
0.0%
$-0.40vs$-0.40
Q4 25
+4.9%
$-0.39vs$-0.41
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.46 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.41 | $-0.39 | +4.9% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-0.40 | $-0.40 | 0.0% | = MET |
Q2 2025 | May 14, 2025 | $-0.43 | $-0.36 | +16.3% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.48 | $-0.34 | +29.2% | ✓ BEAT |
Q4 2024 | Nov 13, 2024 | $-0.61 | $-0.50 | +18.0% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.55 | $-0.52 | +5.5% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.50 | $-0.43 | +14.0% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-1.00 | $-0.23 | +77.0% | ✓ BEAT |
Q4 2023 | Nov 9, 2023 | $-1.14 | $-0.82 | +28.1% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-1.02 | $-1.11 | -8.8% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-0.73 | $-23.43 | -3109.6% | ✗ MISS |
Q1 2023 | Mar 9, 2023 | $-5.88 | $-4.79 | +18.5% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-6.16 | $-6.44 | -4.5% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-5.63 | $-5.32 | +5.5% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-5.35 | $-6.72 | -25.6% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-5.12 | $-5.74 | -12.1% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | $-5.18 | $-5.32 | -2.7% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-6.55 | $-5.04 | +23.1% | ✓ BEAT |
Q2 2021 | May 12, 2021 | $-6.16 | $-7.56 | -22.7% | ✗ MISS |
Frequently Asked Questions about CALC
What is CALC's current stock price?
CalciMedica, Inc. (CALC) is currently trading at $6.35 per share. The stock has moved +29.59% today.
What is the analyst price target for CALC?
The average analyst price target for CALC is $266.00, based on 1 analyst.
What sector is CalciMedica, Inc. in?
CalciMedica, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CALC's market cap?
CalciMedica, Inc. has a market capitalization of $0.09 billion, making it a small-cap company.
Does CALC pay dividends?
No, CalciMedica, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
ELUT
Elutia Inc.
$0.59
Mkt Cap: $0.0B
LTRN
Lantern Pharma Inc.
$3.26
Mkt Cap: $0.0B
LVTX
LAVA Therapeutics N.V.
$1.74
Mkt Cap: $0.0B
MAIA
MAIA Biotechnology, Inc.
$1.22
Mkt Cap: $0.0B
PDSB
PDS Biotechnology Corporation
$0.89
Mkt Cap: $0.0B
RNXT
RenovoRx, Inc.
$0.93
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
TVRD
Tvardi Therapeutics, Inc.
$3.98
Mkt Cap: $0.0B
XLO
Xilio Therapeutics, Inc.
$0.67
Mkt Cap: $0.0B
Explore stocks similar to CALC for comparison